Catheter Precision Financials
This page shows Catheter Precision (VTAK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Catheter Precision generated $420K in revenue in fiscal year 2024. This represents an increase of 2900.0% from the prior year.
Catheter Precision's EBITDA was -$9.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 65.6% from the prior year.
Catheter Precision generated -$9.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 58.7% from the prior year.
Catheter Precision reported -$16.6M in net income in fiscal year 2024. This represents an increase of 38.0% from the prior year.
Catheter Precision held $2.9M in cash against $0 in long-term debt as of fiscal year 2024.
Catheter Precision had 421,296 shares outstanding in fiscal year 2024. This represents a decrease of 80.5% from the prior year.
Catheter Precision's gross margin was 90.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 1140.0 percentage points from the prior year.
Catheter Precision's operating margin was -2676.9% in fiscal year 2024, reflecting core business profitability. This is up 189901.7 percentage points from the prior year.
Catheter Precision's net profit margin was -3962.6% in fiscal year 2024, showing the share of revenue converted to profit. This is up 187930.2 percentage points from the prior year.
Catheter Precision invested $272K in research and development in fiscal year 2024. This represents a decrease of 95.7% from the prior year.
Catheter Precision invested $67K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 294.1% from the prior year.
VTAK Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $226K+6.6% | $212K+48.3% | $143K+11.7% | $128K-3.8% | $133K+38.5% | $96K+12.9% | $85K | $0 |
| Cost of Revenue | $18K+28.6% | $14K+27.3% | $11K+57.1% | $7K+16.7% | $6K-14.3% | $7K-30.0% | $10K | $0 |
| Gross Profit | $208K+5.1% | $198K+50.0% | $132K+9.1% | $121K-4.7% | $127K+42.7% | $89K+18.7% | $75K | $0 |
| R&D Expenses | $276K+78.1% | $155K+50.5% | $103K+1036.4% | -$11K-109.8% | $112K-16.4% | $134K-44.2% | $240K+55.8% | $154K |
| SG&A Expenses | $3.0M+2.5% | $2.9M-17.3% | $3.5M+27.7% | $2.7M-0.6% | $2.7M+94.0% | $1.4M-86.2% | $10.2M+28.6% | $8.0M |
| Operating Income | -$3.0M+35.5% | -$4.7M-31.1% | -$3.6M-37.7% | -$2.6M+4.9% | -$2.7M+56.7% | -$6.3M+90.5% | -$66.5M-709.3% | -$8.2M |
| Interest Expense | $32K | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Income Tax | $78K+108.2% | -$950K-31.2% | -$724K | $0 | $0 | $0 | $0-100.0% | $3K |
| Net Income | -$2.3M+58.8% | -$5.5M-34.9% | -$4.0M-504.6% | -$669K+65.3% | -$1.9M-22.3% | -$1.6M+97.6% | -$66.4M-713.8% | -$8.2M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
VTAK Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $25.5M-0.4% | $25.6M+3.1% | $24.8M-19.3% | $30.7M-6.5% | $32.9M-7.5% | $35.5M-26.7% | $48.5M+188.1% | $16.8M |
| Current Assets | $2.5M+20.6% | $2.0M+139.6% | $854K-79.5% | $4.2M-28.0% | $5.8M-27.0% | $7.9M-38.0% | $12.8M-24.2% | $16.8M |
| Cash & Equivalents | $1.1M+28.3% | $838K+86.2% | $450K-87.4% | $3.6M-36.1% | $5.6M-24.7% | $7.4M-39.4% | $12.2M-23.0% | $15.9M |
| Inventory | $34K-29.2% | $48K-32.4% | $71K+61.4% | $44K-31.3% | $64K+8.5% | $59K-15.7% | $70K | $0 |
| Accounts Receivable | $123K+7.0% | $115K+35.3% | $85K-38.0% | $137K+197.8% | $46K-61.3% | $119K+48.8% | $80K | $0 |
| Goodwill | N/A | N/A | N/A | $0-100.0% | $60.9M0.0% | $60.9M+8.8% | $56.0M | $0 |
| Total Liabilities | $19.0M+0.1% | $19.0M+12.6% | $16.9M+76.9% | $9.5M-13.3% | $11.0M-6.4% | $11.8M-7.1% | $12.6M+66.9% | $7.6M |
| Current Liabilities | $5.3M+14.7% | $4.6M+13.5% | $4.1M+65.4% | $2.5M+21.5% | $2.0M-0.3% | $2.0M-54.1% | $4.5M-41.2% | $7.6M |
| Long-Term Debt | $1.5M0.0% | $1.5M | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $6.8M+3.6% | $6.5M-17.3% | $7.9M-62.6% | $21.2M-3.1% | $21.9M-8.1% | $23.8M-33.7% | $35.9M+287.3% | $9.3M |
| Retained Earnings | -$303.8M-0.7% | -$301.5M-1.7% | -$296.4M-7.5% | -$275.7M-0.2% | -$275.0M-0.7% | -$273.1M-0.6% | -$271.5M-32.4% | -$205.1M |
VTAK Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | -$2.3M | N/A | N/A | N/A | -$12.1M | N/A |
| Capital Expenditures | N/A | N/A | $10K | N/A | N/A | N/A | $37K | N/A |
| Free Cash Flow | N/A | N/A | -$2.3M | N/A | N/A | N/A | -$12.1M | N/A |
| Investing Cash Flow | N/A | N/A | -$10K | N/A | N/A | N/A | -$22K | N/A |
| Financing Cash Flow | N/A | N/A | -$75K | N/A | N/A | N/A | $8.4M | N/A |
| Dividends Paid | N/A | N/A | N/A | $0 | $0 | $0-100.0% | $800K | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
VTAK Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.0%-1.4pp | 93.4%+1.1pp | 92.3%-2.2pp | 94.5%-1.0pp | 95.5%+2.8pp | 92.7%+4.5pp | 88.2% | N/A |
| Operating Margin | -1336.7%+873.6pp | -2210.4%+289.6pp | -2500.0%-471.1pp | -2028.9%+23.7pp | -2052.6%+4518.2pp | -6570.8%+71645.6pp | -78216.5% | N/A |
| Net Margin | -996.0%+1578.5pp | -2574.5%+254.1pp | -2828.7%-2306.0pp | -522.7%+926.2pp | -1448.9%+192.8pp | -1641.7%+76476.0pp | -78117.7% | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -8.8%+12.5pp | -21.3%-5.0pp | -16.3%-14.1pp | -2.2%+3.7pp | -5.9%-1.4pp | -4.4%+132.4pp | -136.9%-88.4pp | -48.5% |
| Current Ratio | 0.46+0.0 | 0.44+0.2 | 0.21-1.5 | 1.68-1.2 | 2.84-1.0 | 3.87+1.0 | 2.86+0.6 | 2.22 |
| Debt-to-Equity | 0.220.0 | 0.23-1.9 | 2.13+1.7 | 0.45-0.1 | 0.500.0 | 0.49+0.1 | 0.35-0.5 | 0.82 |
| FCF Margin | N/A | N/A | -1642.0% | N/A | N/A | N/A | -14223.5% | N/A |
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks.
Financial strength trend (9 signals). 7-9 = strong, 0-3 = weak.
Operating cash flow vs net income. Above 1.0x = cash-backed earnings.
Similar Companies
Frequently Asked Questions
What is Catheter Precision's annual revenue?
Catheter Precision (VTAK) reported $420K in total revenue for fiscal year 2024. This represents a 2900.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Catheter Precision's revenue growing?
Catheter Precision (VTAK) revenue grew by 2900% year-over-year, from $14K to $420K in fiscal year 2024.
Is Catheter Precision profitable?
No, Catheter Precision (VTAK) reported a net income of -$16.6M in fiscal year 2024, with a net profit margin of -3962.6%.
What is Catheter Precision's EBITDA?
Catheter Precision (VTAK) had EBITDA of -$9.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Catheter Precision's gross margin?
Catheter Precision (VTAK) had a gross margin of 90.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Catheter Precision's operating margin?
Catheter Precision (VTAK) had an operating margin of -2676.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Catheter Precision's net profit margin?
Catheter Precision (VTAK) had a net profit margin of -3962.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Catheter Precision's free cash flow?
Catheter Precision (VTAK) generated -$9.3M in free cash flow during fiscal year 2024. This represents a 58.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Catheter Precision's operating cash flow?
Catheter Precision (VTAK) generated -$9.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Catheter Precision's total assets?
Catheter Precision (VTAK) had $27.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Catheter Precision's capital expenditures?
Catheter Precision (VTAK) invested $67K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Catheter Precision spend on research and development?
Catheter Precision (VTAK) invested $272K in research and development during fiscal year 2024.
How many shares does Catheter Precision have outstanding?
Catheter Precision (VTAK) had 421,296 shares outstanding as of fiscal year 2024.
What is Catheter Precision's current ratio?
Catheter Precision (VTAK) had a current ratio of 1.48 as of fiscal year 2024, which is considered adequate.
What is Catheter Precision's debt-to-equity ratio?
Catheter Precision (VTAK) had a debt-to-equity ratio of 1.36 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Catheter Precision's return on assets (ROA)?
Catheter Precision (VTAK) had a return on assets of -59.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Catheter Precision's cash runway?
Based on fiscal year 2024 data, Catheter Precision (VTAK) had $2.9M in cash against an annual operating cash burn of $9.3M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Catheter Precision's Piotroski F-Score?
Catheter Precision (VTAK) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.
Are Catheter Precision's earnings high quality?
Catheter Precision (VTAK) has an earnings quality ratio of 0.56x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.
How financially healthy is Catheter Precision?
Catheter Precision (VTAK) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks.